You have read all your free articles, to continue reading subscribe to read the rest of this content.
New results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of Farxiga, compared to placebo, in patients with heart failure (HF). The reduction in risk of cardiovascular (CV) death was consistent across pre-specifieAlready a subscriber Login You have read all…
Shares of Ipsen and partner Active Biotech plunged last week after Ipsen’s experimental prostate cancer drug Tasquinimod failed during a Phase III trial. Active’s shares dropped 60 percent and Ipsen’s went down by 10 percent. “The data at hand is unambiguous and cannot motivate further Already a subscriber Login You…
AstraZeneca announces results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique(ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA). The primary efficacy endpoint of time to fiAlready a subscriber Login You have read all your…
The company has presented data from two patients with liver metastases of colorectal cancer origin treated with ACT in the clinical Phase I ACTIVATE trial. The presented radiological results from these two patients suggest an improved response to standard of care chemotherapy in the tumors that aAlready a subscriber Login…
